Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

Human Vaccines & Immunotherapeutics
Selma AddouJean-Marie Michot

Abstract

Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor outcomes, and new treatment strategies are needed for these young adults. There are several well-documented cases in the medical literature on hematologic cancer remission following natural human viral infections. Therefore, hoping to reproduce these spontaneous tumor regressions, researchers have been investigating various viruses with oncolytic properties. There is a high rationale for using virotherapy in the treatment of Hodgkin lymphoma, in which tumor cells are often infected with the Epstein-Barr virus. Modern viral technologies and current knowledge about the relationship between viruses and cancer could accelerate the discovery of effective viral oncolytic therapies. This article reviews the use of oncolytic viruses as innovative therapies for treating Hodgkin lymphoma.

References

Mar 20, 1971·Lancet·Z Zygiert
May 16, 1981·Lancet·A M TaqiA F Fleming
May 1, 1993·The American Journal of Pediatric Hematology/oncology·A L Billett, S E Sallan
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LazarusM M Horowitz
Dec 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G AkpekR J Jones
Mar 16, 2002·Journal of Clinical Pathology·S A PileriH Stein
Oct 3, 2002·British Journal of Haematology·Daniel MolinGunilla Enblad
Oct 15, 2003·Clinical Lymphoma·Tommy AlainAnna E Kossakowska
Feb 25, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yi ZhangStephen G Emerson
May 27, 2006·Experimental Hematology·Hooi Tin OngKah-Whye Peng
Mar 10, 2007·Current Cancer Drug Targets·Wang Yu, Hu Fang
Mar 30, 2007·British Journal of Haematology·Gough G AuDarren R Shafren
Nov 29, 2007·Journal of Clinical Pathology·G Kapatai, P Murray
Apr 22, 2008·Nature Immunology·Eric VivierSophie Ugolini
Jan 20, 2009·Recent Patents on CNS Drug Discovery·Amy HaseleyBalveen Kaur
Feb 11, 2009·Current Topics in Microbiology and Immunology·S J Russell, K W Peng
Dec 24, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kathryn Ottolino-PerryJ Andrea McCart
Jul 31, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kevin J HarringtonChristopher M Nutting
Sep 8, 2010·The New England Journal of Medicine·Andreas EngertVolker Diehl
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jan 1, 2009·Mediterranean Journal of Hematology and Infectious Diseases·Giuseppina MassiniStefan Hohaus
Feb 9, 2012·Advances in Virology·M H Verheije, P J M Rottier
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Jul 12, 2012·Nature Biotechnology·Stephen J RussellJohn C Bell
Jun 4, 2013·Vaccine·Winnie M ChanGrant McFadden
Dec 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine M BollardCliona M Rooney
Mar 7, 2014·Science Translational Medicine·Dmitriy ZamarinJames P Allison
Mar 8, 2014·Frontiers in Immunology·Maxine Bauzon, Terry Hermiston
Jul 6, 2014·Nature Reviews. Cancer·Brian D LichtyJohn C Bell
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Dec 23, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Timothy P CripeCaroline J Breitbach
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Jun 27, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Norman WollerFlorian Kühnel
Sep 2, 2015·Nature Reviews. Drug Discovery·Howard L KaufmanAndrew Zloza
Mar 5, 2016·Oncoimmunology·Jonathan PolLorenzo Galluzzi
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Igor PuzanovRobert H I Andtbacka
Jul 14, 2016·EBioMedicine·Caroline J BreitbachJohn C Bell
Jul 22, 2016·JAMA Oncology·Sean E LawlerE Antonio Chiocca
Jan 1, 2015·Oncolytic Virotherapy·Jovian J Tsang, Harold L Atkins

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the National Comprehensive Cancer Network : JNCCN
Richard T HoppeNCCN Hodgkin Lymphoma
Nature Reviews. Disease Primers
Monographs in Clinical Cytology
Pio Zeppa, Immacolata Cozzolino
Nihon rinsho. Japanese journal of clinical medicine
Sadao Aoki
Monographs in Clinical Cytology
Lambert Skoog, Edneia Tani
© 2021 Meta ULC. All rights reserved